At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 78 enrolled
Drug / intervention
pembrolizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase 2 Trial of ACP-196 and Pembrolizumab Immunotherapy Dual CHECKpoint Inhibition In Platinum Resistant Metastatic Urothelial Carcinoma (RAPID CHECK Study)
In Brief
A Phase 2 clinical trial evaluating pembrolizumab and ACP-196 in combination with pembrolizumab for Metastatic Urothelial Carcinoma. Completed, enrolled 78 participants across 7 sites.
Detailed Summary
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Metastatic Urothelial Cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Urothelial Carcinoma
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartApr 2015
Primary CompletionFeb 2018
Study CompletionApr 2018
TodayJul 2026
First PostedJan 30, 2015
Enrollment StartApr 1, 2015
Primary CompletionFeb 1, 2018
Study CompletionApr 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 11.4 years ago
Interventions
pembrolizumabdrug
ACP-196 in combination with pembrolizumabdrug